Germany's AMRadV ordinance treats a cannabis flower that has passed through ionising radiation as a different regulatory object than one that has not. That single distinction settles more export conversations than price does.
Cannabis irradiation is a post-harvest decontamination step that applies gamma, electron beam, or X-ray energy to dried flower to cut its microbial load. Canadian Licensed Producers reach for it when a batch cannot meet the microbial acceptance criteria of the destination market. Cannabinoid content survives the treatment. Some terpenes do not.
For an LP shipping into Germany, Australia, or the Canadian medical channel, the practical question is rarely whether the technology works. It is whose acceptance criterion your batch gets measured against, who is licensed to perform the treatment, and what that treatment costs you in aroma.
Cannabis irradiation and the microbial limits that drive it
Every remediation decision starts with an acceptance criterion, not with a technology choice. Under subsection 93(3) of the Cannabis Regulations, dried cannabis must not carry microbial or chemical contaminants beyond generally accepted tolerance limits. Those limits come from a publication named in Schedule B to the Food and Drugs Act, and they must suit the intended and reasonably foreseeable use of the product. Health Canada has confirmed to licence holders that the limits in European Pharmacopoeia general chapter 5.1.8 remain acceptable for dried cannabis.
Chapter 5.1.8 was written around herbal drugs for oral use. Chapter 5.1.4 sets criteria by route of administration, and its inhalation figures are much tighter: a total aerobic microbial count of 100 CFU/g, a combined yeast and mould count of 10 CFU/g, and specified pathogens absent. Two chapters. Two different answers about the same jar of flower.
Where the gap usually shows up
Most Licensed Producers find the problem at the buyer's incoming quality control rather than at their own batch release. The certificate of analysis reads as compliant against a Canadian 5.1.8 benchmark. A German importer reads the same numbers against an inhalation-route criterion and rejects the lot. Nothing about the flower changed. The ruler changed.
Which means the opening question in an export negotiation is not whether you irradiate. It is which chapter the buyer's pharmacist has open when they read your contaminant results.
How Germany, Australia and Canada treat irradiated flower
Three markets, three postures. None of them bans ionising treatment outright, and none of them waves it through either.
| Market | Governing instrument | Position on ionising treatment | What the LP has to produce |
|---|---|---|---|
| Germany | AMRadV, under the Arzneimittelgesetz | Permitted with product-level authorisation | Validated process, GMP-certified irradiator, proof quality is not impaired |
| Australia | TGO 93, sections 9 and 13 | Permitted, ethylene oxide prohibited | Treatment performed under GMP with acceptable GMP evidence |
| Canada | Cannabis Regulations, subsection 93(3) | No method mandated, limits follow intended use | Schedule B tolerance limits, validated process under GPP |
In Germany the authorisation sits with BfArM under AMRadV, and it attaches to the treated product rather than to the exporter in general. The company carrying out the irradiation must hold a valid GMP certificate. The bioburden at which treatment occurs has to be specified, the process has to be validated, and the applicant has to show that plant constituents are not adversely affected and that no harmful residues remain. Anyone supplying the German medical channel is inside that regime whether they treat their own flower or not.
Australia handles the same issue inside its quality standard instead of a separate ordinance. Section 9(a) of TGO 93 requires that decontamination not adversely affect product quality, and section 9(b) prohibits ethylene oxide. The Therapeutic Goods Administration has also confirmed that any decontamination step, irradiation included, must be carried out under GMP. That means a licensed Australian site, or an overseas site with acceptable GMP evidence under subsection 13(3). It is a manufacturing obligation, and it lands squarely in Australian import compliance planning.
Here is the part producers underestimate. If your commercial plan rests on one German importer and you have not seen their AMRadV coverage for your specific product in writing, you do not have a plan. You have an assumption. Confirm it before you allocate harvest.
What irradiation does to cannabinoids and terpenes
The cannabinoid question has been settled in the literature for a decade. Hazekamp's 2016 study in Frontiers in Pharmacology found that gamma treatment of medicinal cannabis left THC and CBD content unchanged while reducing the more volatile monoterpenes. Jerushalmi and colleagues, writing in the Journal of Cannabis Research in 2020, compared gamma, electron beam, and cold plasma for fungal reduction in cannabis inflorescences and reported substantial reductions across all three methods.
So the potency number on your accredited test report survives. The aroma your buyer registered when they opened the sample jar may not, and monoterpenes carry most of what a procurement manager actually notices.
Sequencing is where this gets expensive
Science is not the hard part here. Timing is. Your terpene data was generated before treatment, and your buyer's expectation was set by that document. When a supply agreement references a pre-treatment certificate and the pharmacy receives post-treatment flower, the dispute is already written into the contract. Nobody argues about cannabinoids. They argue about aroma.
Producers selling on terpene expression have a straight financial reason to hold bioburden down during cultivation instead of correcting it after harvest. Cleaner airflow and tighter post-harvest handling cost less than a lost aroma profile and a renegotiated price. That is a cultivation capital argument, not a marketing one.
The 4-question remediation check before you sign
Run this before a supply agreement is signed, not after a pallet is held at the border. Four questions, in order, each with a document behind it.
1. Which acceptance criterion applies in the destination market?
Ask the buyer to name the pharmacopoeial chapter and the route of administration they are testing against. Put it in the specification annex, not in an email thread.
2. Who performs the treatment, and are they certified for it?
The irradiating site needs current GMP certification, and its location decides which regulator audits it. Ask for the certificate number and the expiry date, then diarise the renewal.
3. Is the treated product authorised in that market?
In Germany this means an AMRadV authorisation covering the product being placed on the market, held by whoever places it there. Establish who holds it before you quote a volume.
4. Which certificate does the contract reference?
Pre-treatment and post-treatment results diverge on terpenes. Name the certificate that governs acceptance, and name the tolerance band around it.
Answer all four and remediation stops being a risk and becomes a line item. Question four is the one that gets skipped. It should not be.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, growing indoor, hand-trimmed flower from refined genetics with full batch traceability. Our ISO/IEC 17025 batch testing and export authorisation under the Cannabis Act put complete contaminant and terpene data in an importer's hands early, before a remediation decision is even on the table. That is how supply into the German and Australian medical channels ought to begin.
If you are qualifying a Canadian supplier this quarter, ask for the microbial data first and the price second. Our export team can send batch-level contaminant and terpene results for current lots, together with the certification documentation your regulatory affairs group will request. Talk to the AlphaLeaf export team. Ask before the batch ships.
Frequently Asked Questions
Does irradiation change the THC or CBD content of cannabis flower?
Published research on medicinal cannabis found that gamma treatment left THC and CBD content unchanged. The measurable effect sits in the terpene fraction, where the more volatile monoterpenes are reduced. Potency figures on a certificate of analysis therefore hold up better than aroma does.
Do German importers accept irradiated Canadian cannabis?
Yes, provided the required authorisation is in place. Under AMRadV, medicinal products treated with ionising radiation need authorisation from BfArM before they can be marketed in Germany, and the company performing the irradiation must hold a valid GMP certificate. Confirm in writing who holds that authorisation for your product.
Does Australia allow irradiated medicinal cannabis?
Australia permits decontamination by irradiation, but section 9(a) of TGO 93 requires that it not adversely affect product quality and section 9(b) prohibits ethylene oxide. The TGA also requires the decontamination step to be carried out under GMP, either at a licensed Australian site or an overseas site with acceptable GMP evidence.
Does Health Canada require cannabis to be irradiated?
No. Canadian rules set contaminant limits rather than mandating a treatment method. Subsection 93(3) of the Cannabis Regulations requires microbial and chemical contaminants to stay within generally accepted tolerance limits appropriate to the intended use. Health Canada has indicated that European Pharmacopoeia 5.1.8 limits remain acceptable for dried cannabis.
Why does the same batch pass in Canada and fail in Germany?
Usually because two different pharmacopoeial chapters are being applied. Chapter 5.1.8 is written around herbal drugs for oral use, while chapter 5.1.4 sets tighter inhalation-route criteria, including a total aerobic count of 100 CFU/g and a yeast and mould count of 10 CFU/g. The flower did not change. The acceptance criterion did.
Should a certificate of analysis be issued before or after decontamination?
Contract for the one that governs acceptance and say so explicitly. Terpene results differ before and after treatment, so an agreement that references pre-treatment data while the buyer receives post-treatment flower builds in a dispute. Naming the governing certificate and its tolerance band removes the ambiguity.
